Literature DB >> 16344917

Propagation of population PK and PD information using a Bayesian approach: dealing with non-exchangeability.

Aristides Dokoumetzidis1, Leon Aarons.   

Abstract

The aim of this work is to implement a conservative prior that safeguards against population non-exchangeability of prior and data likelihood, in the framework of population pharmacokinetic/pharmacodynamic analysis, incorporating multi-level hierarchical modelling. Three different exercises were performed: (i) we investigated the use of parametric priors in the multilevel hierarchical modelling framework; (ii) we assessed the average performance of the multilevel hierarchical model compared to the standard mixed effect model, considering also some interesting extreme cases and (iii) we implemented an application with a small Proof of Principle (PoP) study, which demonstrates the propagation of information across PD studies using multilevel modelling. Fitting with the 4-level model and informative parametric priors performed similar to a meta-analysis of the test datasets combined with the datasets that the priors came from, demonstrating that parametric priors can be used alternatively to meta-analysis. Further, the 4-level model gave posterior distributions which had larger uncertainty but at the same time were unbiased, compared to the 3-level model, and therefore implements a more conservative prior in a formal way, which is appropriate when the prior and the test populations are not exchangeable. For the application with the PoP study, the statistical power of detecting the difference in potency between two drugs, when inter-study variability was present, was greater when an extra level in the hierarchical model to account for it, was used. In conclusion, by applying the prior one hierarchical level above the level of the parameters of interest, we implemented a more conservative prior, compared to applying the prior directly on the parameters of interest. The approach is equivalent to Bayesian individualization, offers a safeguard against bias from the prior and also avoids the danger of the data being overwhelmed by a strong prior.

Entities:  

Mesh:

Year:  2005        PMID: 16344917     DOI: 10.1007/s10928-005-0037-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  8 in total

1.  The combination of population pharmacokinetic studies.

Authors:  J Wakefield; N Rahman
Journal:  Biometrics       Date:  2000-03       Impact factor: 2.571

2.  Bayesian analysis of population PK/PD models: general concepts and software.

Authors:  David J Lunn; Nicky Best; Andrew Thomas; Jon Wakefield; David Spiegelhalter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

3.  Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics.

Authors:  Michael G Dodds; Paolo Vicini
Journal:  Ann Biomed Eng       Date:  2004-09       Impact factor: 3.934

4.  Analysis of population pharmacokinetic data using NONMEM and WinBUGS.

Authors:  Stephen B Duffull; Carl M J Kirkpatrick; Bruce Green; Nicholas H G Holford
Journal:  J Biopharm Stat       Date:  2005       Impact factor: 1.051

5.  Propagation of population pharmacokinetic information using a Bayesian approach: comparison with meta-analysis.

Authors:  Aristides Dokoumetzidis; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

6.  A Bayesian design and analysis for dose-response using informative prior information.

Authors:  Michael K Smith; Scott Marshall
Journal:  J Biopharm Stat       Date:  2006       Impact factor: 1.051

7.  A Bayesian approach to nonlinear random effects models.

Authors:  A Racine-Poon
Journal:  Biometrics       Date:  1985-12       Impact factor: 2.571

8.  Estimation of population pharmacokinetic parameters in the presence of non-compliance.

Authors:  Song Mu; Thomas M Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

  8 in total
  2 in total

1.  Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.

Authors:  Elin Svensson; Jan-Stefan van der Walt; Karen I Barnes; Karen Cohen; Tamara Kredo; Alwin Huitema; Jean B Nachega; Mats O Karlsson; Paolo Denti
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

2.  Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia.

Authors:  Anning Li; Shuangmin Ji; Dai Zhang; Chuanyue Wang; Weihua Yue; Hao Yan; Fang Dong; Canjun Ruan; Wenbiao Li; Wei Lu
Journal:  BMJ Open       Date:  2018-08-17       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.